BAVARIAN NORDIC erhält 20 Mio$-Auftrag von der US-Regierung - 500 Beiträge pro Seite

[smallpox]

Morgen sind mal wieder mindestens 50% drin !!!

Bavarian Nordic and the US Department of Health and Human Services (HHS) sign contract for development of MVA-BN as a safe smallpox vaccine for the US

HHS Secretary of Health Tommy G. Thompson today announced that Bavarian Nordic A/S has been awarded a three-year contract with the US National Institute of Allergy and Infectious Diseases (NIAID) to develop Bavarian Nordic`s proprietary MVA-BN safe smallpox vaccine. A total of two contracts have been awarded under the US government`s funding program resulting in a total funding of $ 20 million during the first twelve months.

Please find the full press release and further information on our website:
http://www.bavarian-nordic.com/press2003
Available as full text and downloadable in both English and Danish

Yours sincerely
Bavarian Nordic

[smallpox]

Hier der ganze Text. Aus dem geht hervor, dass sich BAVA bei dem Forschungs- und Produktionsauftrag der US-Gesundheitsbehörde in Konkurrenz mit Acambis befinden. Quasi im Wettbewerb sollen beide zeigen, wer der bessere Hersteller ist und gleichzeitig den sichersten Pockenimpfstoff auf Grundlage des MVA-BN entwickelt und getestet hat.

Acambis hat da schlechte Karten. Die haben schon etlichen Regierungen vieles versprochen aber letztlich immer nur vertröstet. Ausserdem spricht es für sich, dass die US-Regierung einer relativ unbekannten dänischen Firma gleichrangig den Auftrag erteilt hat.

BAVA hat z. B. bereits 1 Mio Dosen an die deutsche Bundeswehr geliefert. Ausserdem wurde ihr MVA bereits in den siebziger Jahren völlig komplikationslos an ca 150 000 Deutsche getestet. Die haben eindeutig die Nase vorn.


Announcement no. 04-03
25 February 2003

Bavarian Nordic and the US Department of Health and Human Services (HHS) sign contract for development of MVA-BN as a safe smallpox vaccine for the US

HHS Secretary of Health Tommy G. Thompson today announced that Bavarian Nordic A/S has been awarded a three-year contract with the US National Institute of Allergy and Infectious Diseases (NIAID) to develop Bavarian Nordic’s proprietary MVA-BN safe smallpox vaccine. A total of two contracts have been awarded under the US government’s funding program resulting in a total funding of $ 20 million during the first twelve months.

Under the contract Bavarian Nordic must develop a plan for large-scale manufacture of MVA-BN to demonstrate how Bavarian Nordic could deliver up to 30 million doses to the federal government.

The full text of today’s HHS statement, including the comments made by Mr. Tommy G. Thompson, is attached.

Bavarian Nordic has been developing MVA-BN as a safe smallpox vaccine for the last three years and has already produced a comprehensive package of pre-clinical and clinical data that meets several of the objectives outlined in the US contract. Bavarian Nordic is the only company to have already completed small animal studies and a clinical Phase I study in healthy volunteers, demonstrating the excellent safety and immunogenicity of MVA-BN.

The collaboration with the HHS is not expected to affect Bavarian Nordic’s expectations for 2003, which remain a turnover of DKK 500 mill. and a profit before tax of DKK 250 mill.

Copenhagen, 25 February 2003
Asger Aamund, Chairman of the Board

.....
About MVA-BN
Bavarian Nordic’s key technology and product platform is the MVA-BN vaccine technology. MVA-BN is short for “Modified Vaccinia Ankara – Bavarian Nordic”, and Bavarian Nordic believes this technology holds great promise as the vaccine vector of choice for the future.

Bavarian Nordic has been developing MVA-BN as a vaccine vector since 1995 and as a smallpox vaccine since 1998. MVA was originally developed in Germany in the 1950’s and 1960’s, from Vaccinia Ankara, and was attenuated through more than 570 passages in chicken embryo fibroblasts (CEF cells). The goal was to attenuate and modify a classical smallpox vaccine, Vaccinia Ankara, to a safe smallpox vaccine. The resulting virus, MVA, was used for pre-vaccinating more than 120,000 high-risk individuals in Germany during the smallpox eradication campaigns in the 1970’s without any severe side effects.

MVA-BN has been developed by Bavarian Nordic as a monoclonal virus from MVA passage 575. MVA-BN includes a high antibody and cellular immune response and is likely to be the only smallpox vaccine, which is safe even in immune compromised individuals. Based upon these qualities Bavarian Nordic is developing a number of recombinant vaccines based upon MVA-BN. A series of patents and patent applications covers various aspects of the MVA-BN technology.

About Bavarian Nordic
Bavarian Nordic is a world leader in the research, development and manufacturing of vaccines and immuno-therapy against infectious diseases. The company has ongoing clinical programs in HIV and smallpox, as well as pre-clinical and research programs within a number of infectious diseases.
------------------------------------------------------------------------

The following from: www.hhs.gov/news

HHS ANNOUNCES CONTRACTS TO DEVELOP SAFER SMALLPOX VACCINES
 
HHS Secretary Tommy G. Thompson today announced the award of two contracts totaling up to $20 million in first-year funding to develop safer smallpox vaccines. The three-year contracts were awarded to Bavarian Nordic A/S of Copenhagen, Denmark, and Acambis Inc. of Cambridge, Mass. The National Institute of Allergy and Infectious Diseases (NIAID) will administer the contracts.
 
“To protect ourselves from the remote but extremely grave threat of a deliberate release of smallpox virus, we need a vaccine that can be safely given to all Americans, including individuals with weakened immune systems, children and pregnant women,” said Secretary Thompson. “The new contracts will help us meet this need by accelerating research on second-generation smallpox vaccines.”
 
“Milestone-driven contracts such as these are one way NIAID is eliciting industry participation in the search for new and improved vaccines,” noted NIAID Director Anthony S. Fauci, M.D. “These programs are designed to get reliable products into the pipeline in an economically efficient and scientifically sound manner,” he added.
 
Acambis and Bavarian Nordic will develop, manufacture and conduct safety trials of modified vaccinia virus Ankara (MVA) vaccine candidates. Vaccinia virus, a close relative of smallpox virus, is used in traditional smallpox vaccines. A live, replicating virus, vaccinia can cause side effects, which on rare occasions can be serious and potentially life-threatening. Pregnant women and people with compromised immune systems, such as patients on chemotherapy or people with HIV/AIDS, cannot receive the current smallpox vaccine at all.
 
MVA is a strain of vaccinia that cannot replicate inside human cells and therefore cannot cause dispersed infection. An MVA-based vaccine given to more than 120,000 people during the smallpox eradication campaign in Germany in the 1970s had an excellent safety record. When smallpox was declared eradicated in 1980, however, the need for smallpox vaccines vanished, and research on MVA for that purpose ended.
 
Because of the urgent need for safer smallpox vaccines, the new contracts emphasize timely completion of predetermined objectives. For example, within the first six months the companies must produce several thousand doses of their prototype vaccine along with data indicating its effectiveness in animal models. Following approval of human study protocols, the companies will conduct tests of the vaccines’ safety in healthy adults. Finally, the companies must develop a plan for large-scale manufacture of the candidate vaccines and show how they could deliver up to 30 million doses to the federal government.   
  
NIAID is a component of the National Institutes of Health (NIH), which is an agency of the Department of Health and Human Services.  NIAID supports basic and applied research to prevent, diagnose, and treat infectious and immune-mediated illnesses, including HIV/AIDS and other sexually transmitted diseases, illness from potential agents of bioterrorism, tuberculosis, malaria, autoimmune disorders, asthma and allergies.

[smallpox]

Da trifft es sich natürlich auch gut, dass BAVA sich zur Zeit in NY auf der Investorenkonferenz präsentieren:

BIO CEO & Investor Conference 2003
Waldorf=Astoria, New York, NY
February 25-27

Es sollte mich in diesem Zusammenhang nicht wundern, wenn dort auch einige Investoren zu der Überzeugung kommen, dass BAVA mit einem KGV von unter 2, ihren glänzenden Geschäftsaussichten beim MVA-BN und der HIV-Pipeline ein echtes Schnäppchen !!! ist.

M.a.W.: ich rechne Mittwoch oder Donnerstag noch mit einer weiteren Meldung !!!

About This Event
The Biotechnology Industry Organization welcomes you to attend the BIO CEO & Investor Conference 2003, the industry’s own investor conference.

The BIO CEO & Investor Conference is the industry`s own investor conference. The meeting provides a neutral forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, investor sessions focused on hot technologies and therapeutics, roundtables on key business issues, company presentations, one-on-one meetings, and networking opportunities. To view the preliminary conference program please click on the following link Conference Program.

.....

siehe auch: http://www.bio.org/ceo/2003/present/

[skipper2002]

na das interesse hält sich aber in grenzen....wo kauf ich das ding denn am besten?
deutschland is wohl nicht so gut

[smallpox]

BAVA.CO ist an der Copenhagen Stock Exchange (CSE) gelistet.
In Deutschland werden sie kaum gehandelt.

[smallpox]

Sorry, war nicht korrekt übersetzt:

1. Das Geld für das 20 Mio$-Programm teilen sich BAVA und Aventis.

2. Wer am besten und schnellsten in der Lage ist, 30 Mio Dosen sicheren MVA-Pockenimpfstoffs in den USA zu produzieren, erhält dann den entsprechenden Auftrag.

3. Trotz alledem: der Auftrag könnte zu einem weiteren Bumerang für Ulla Schmidt werden. Sie ist blamiert, weil sie die intensive Forschung für den MVA nicht einmal in Betracht gezogen hat.

4. BAVA zeigt weltweit mittlerweile unübersehbar Kompetenz und Marktführerschaft in Sachen MVA.

5. Wenn BAVA wie erwartet den Auftrag zur Herstellung ihres MVA-Pockenimpfstoffes in den USA erhalten, ist damit auch die Zulassung für den hiesigen Markt viel einfacher. Die US-Zulassungsrichtlinien sind strenger. Daher ist die Zulassung in Deutschland keine 4 bis 5-jährige Angelegenheit mehr.

6. Angesichts der steigenden Nachfrage nach Elstree-BN und MVA-BN dürfte BAVA bald eine Preiserhöhung und einen Ausau der Produktionskapazitäten für MVA ins Auge fassen.

7. Wer jetzt nicht einsteigt, für den ist der Zug für eine ganze Weile erst mal abgefahren !!!

[smallpox]

Es wird spannend!!! Hier die Reuters-Meldung:

U.S. contracts for safer smallpox vaccine
By Maggie Fox, Health and Science Correspondent

WASHINGTON, Feb 25 (Reuters) - Citing the need for its smallpox vaccination program to include pregnant women, people with weakened immune systems and other vulnerable groups, the U.S. government on Tuesday announced contracts with a Danish and a British company to make a safer vaccine.

The Health and Human Services Department said it had awarded contracts to Bavarian Nordic A/S (København: BAVA.CO - nyheder) of Copenhagen, Denmark, and Acambis Inc. of Cambridge, Massachusetts, a subsidiary of Britain`s Acambis Plc (London: ACM.L - nyheder) .

The government has met tough resistance in its drive to give the current smallpox vaccine, which is made using a live virus related to the smallpox virus, to select health care workers and the military.

The virus, vaccinia, is usually harmless, but in people with suppressed immune systems -- such as cancer patients, those with HIV, and some pregnant women -- vaccinia can cause severe and even deadly side effects.

Routine smallpox vaccination in the United States stopped in 1972 and the disease was deemed eradicated in 1980. But the U.S. government now believes a biological attack using smallpox is possible, and even more likely if there is a war against Iraq. Iraq is believed by the United States to have developed a number of biological weapons, perhaps including smallpox.

The military is in the process of vaccinating up to half a million troops, and states are supposed to be vaccinating up to 450,000 health care workers who will then vaccinate larger groups if there is an outbreak.

Currently, the Wyeth DryVax vaccine is being used, but the search is on for a vaccine that is safe for everyone.

The U.S. health department said it was spending $20 million on two three-year contracts to the rival companies, both of which are already developing smallpox vaccines, to help them develop safer vaccines.

"To protect ourselves from the remote, but extremely grave, threat of a deliberate release of smallpox virus, we need a vaccine that can be safely given to all Americans, including individuals with weakened immune systems, children and pregnant women," Health and Human Service Secretary Tommy Thompson said in a statement.

The companies will work on a formula using a weakened form of vaccinia called modified vaccinia virus Ankara, or MVA.

An MVA vaccine worked safely in Germany in the 1970s, but the program was scrapped when smallpox was eradicated.

The U.S. smallpox vaccination program is off to a much slower start than anticipated. Thompson had predicted that most, if not all, 450,000 health workers would be vaccinated by this week, one month after starting.

However, as of last week, only 4,213 people had been vaccinated, according to the U.S. Centers for Disease Control and Prevention.

"I`m disappointed by the response," Thompson told reporters last week. He said people did not understand what a threat smallpox is.

"I think we need to do a better job to convince them this is a risk," he said.

Unions and other groups representing health care workers have opposed the vaccination program because it does not provide for compensation and time off for workers made sick by the vaccine. Thompson said his department was working with Congress to develop a plan to cover these concerns.

"As soon as we get a compensation fund out there I think it is going to move quickly," he said.

[smallpox]

..... wer hat sich denn da bei 191.50 DKK die Finger verbrannt?

Jemand hier aus dem Board?

[beamer01]

Sag mal smallpox, wo schaust du dir immer die Kurse an ? Bin mit den dt. online-Kursen nicht so wirklich zufrieden...
Ansonsten macht es heute ja mal wieder Spaß den Kurs zu verfolgen !!

[smallpox]

Gestern bei Börsenschluss: 105 DKK
Eröffnung heute: 121 DKK
Spitze heute: 191,50 DKK
14:08 Uhr: 121,50 DKK (121,5 zu 124)

Es ist interessant, wann heute die Amerikaner einsteigen. ? !!!